Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders

References

• Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5(1), 44–51 (2003).
   PubMed Web of Science ®Google Scholar
• Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br. J. Cancer 89(8), 1389–1394 (2003).
   PubMed Web of Science ®Google Scholar
• Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 21(9), 1874–1881 (2003).
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9), 2635–2642 (2004).
   PubMed Web of Science ®Google Scholar
• Cheson BD. Radioimunotherapy of non-Hodgkin lymphoma. Blood 101(2), 391–398 (2003).
   PubMed Web of Science ®Google Scholar
• Davies AJ. Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. Q. J. Nucl. Med. Mol. Imaging 48(4), 305–316 (2004).
   PubMedGoogle Scholar
• Foss F. Clinical experience with denileukin diftitox (Ontak). Semin. Oncol. 33(S3), S11–S16 (2006).
   PubMed Web of Science ®Google Scholar
• Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 56(11), 2590–2595 (1996).
   PubMed Web of Science ®Google Scholar
• Eklund JW, Kuzel TM. Denileukin diftitox: a concise clinical review. Expert Rev. Anticancer Ther. 5(1), 33–38 (2005).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Meneghetti C, Rosenblum M et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79(10), 2547–2554 (1992).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Craig FE, Meneghetti C et al. Phase I trial of 90-minute infusion of the fusion toxin BAD486IL in hematological cancers. Cancer Res. 53(17), 3930–3934 (1993).
   PubMed Web of Science ®Google Scholar
• Kuzel TM, Rosen ST, Gordon LI et al. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486I-2: efficacy in mycosis fungoides and other non-Hodgkin’s lymphomas. Leuk. Lymphoma 11(5–6), 369–377 (1993).
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Saleh MN, Kuzel TM et al. Phase I trial of a ligand fusion-protein (DAB389-IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91(2), 399–405 (1998).
   PubMed Web of Science ®Google Scholar
• Kuzel T. DAB389-IL-2 (Denileukin Diftitox, Ontak): review of clinical trials to date. Clin. Lymphoma 1(S1), S33–S36 (2000).
   Google Scholar
• Ontak®, package insert. Ligand Pharmaceuticals, San Diego, CA, USA
   Google Scholar
• Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19(2), 376–388 (2001).
   PubMed Web of Science ®Google Scholar
• Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB389IL-2 (Denileukin diftitox, Ontak®) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma 1(4), 298–302 (2001).
   PubMedGoogle Scholar
• Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am. J. Hematol. 58(1), 87–90 (1998).
   PubMed Web of Science ®Google Scholar
• Foss F, Demierre MF, DiVenuti G. A Phase I trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106(2), 454–457 (2005).
   PubMed Web of Science ®Google Scholar
• Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin ditfitox. Blood 100(4), 1399–1403 (2002).
   PubMed Web of Science ®Google Scholar
• Dang NH, Hagemeister FB, Pro B et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 22(20), 4095–4102 (2004).
   PubMed Web of Science ®Google Scholar
• Dang NH, Pro B, Hagemaister F et al. Phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin’s lymphoma. Blood 106(11), A936 (2005).
   Google Scholar
• Frankel AE, Fleming DR, Hall PD et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res. 9(10), 3555–3561 (2003).
   Google Scholar
• Morgan SJ, Seymour JF, Prince HM, Westerman DA, Wolf MM. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including case with chromosome 17p deletions and without detectable CD25 expression. Clin. Cancer Res. 10(10), 3572–3575 (2004).
   Google Scholar
• Lilly M, Kuriakose P, Turturro F et al. A Phase II study of denileukin diftitox (Ontak) in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 23(S16), 6649 (2005).
   Google Scholar
• Frankel AE, Surendranathan A, Black JH et al. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 106(10), 2158–2164 (2006).
   PubMed Web of Science ®Google Scholar
• Ho V, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104(4), 1224–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Antin JH. The pathophysiology of graft versus host disease. In: Hematopoietic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds). Blackwell Science Inc., Madden, MA, 19–27 (1999).
   Google Scholar
• Shaughnessy PJ, Bachier C, Grimley M et al. Denileukin diftitox for the treatment of steroid-resistant acute graft versus-host disease. Biol. Blood Marrow Transplant. 11(3), 188–193 (2005).
   PubMed Web of Science ®Google Scholar
• Duvic M, Kuzel TM, Olsen EA et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (Ontak®). Clin. Lymphoma 2(4), 222–228 (2002).
   PubMedGoogle Scholar